Pretzel Therapeutics Launches With $72.5 Million Series A Financing To Pioneer Mitochondrial Therapies
Pretzel Therapeutics Launches With $72.5 Million Series A Financing To Pioneer Mitochondrial Therapies
09/12/22, 10:03 AM
Location
bostonMoney raised
$72.5 million
Industry
biotechnology
Round Type
series a
Pretzel Therapeutics, a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with a $72.5 million Series A financing to pioneer novel therapies to modulate mitochondrial function. The financing was led by ARCH Venture Partners and Mubadala Capital with participating investors HealthCap, Cambridge Innovation Capital, Cambridge Enterprise, Angelini Ventures, GV, Invus, Eir Ventures, GU Ventures, and Karolinska Institutet Holding.
Company Info
Location
trapelo rd
boston, massachusetts, united states
Additional Info
Pretzel Therapeutics is a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies. Pretzel was founded by leading academic experts in mitochondrial biology and is backed by a world-class investor syndicate. The company is headquartered in Waltham, MA and has research facilities in Gothenburg, Sweden. For more information, visit www.pretzeltx.com.